StockData
Renalytix plc logo

Renalytix plc (RNLXY) stock

RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)

Close on Oct 19, 2026Market cap $375.75MP/E –Yield –

Earnings

Renalytix's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2024
$500.00K
EPS, Q3 FY2024
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Renalytix's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2025ended Sep 30, 2024Oct 1, 2024during market hours–––Release
Q3 FY2024ended Mar 31, 2024May 15, 2024before the open$500.00K––Release
Q2 FY2024ended Dec 31, 2023Feb 15, 2024before the open$700.00K–-$0.09Release
Q1 FY2024ended Sep 30, 2023Nov 14, 2023before the open$500.00K––Release
Q4 FY2023ended Jun 30, 2023Sep 28, 2023before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Renalytix has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Renalytix puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Renalytix filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. Update
  4. Results
  5. Results
  6. Results
  7. Update
  8. Update
  9. Update
  10. Update
  11. Results
  12. News
  13. Update
  14. Update
  15. Update

See a number that looks wrong?